Drug Pipeline

Remibrutinib Clinical Trials

Data updated daily from ClinicalTrials.gov — last refresh 2026-06-12
14
Active Studies
7
Recruiting
11
Phase 3
2
Top Sponsors
8
Changes, 30 Days
What Changed in the Last 30 Days
DetectedTrialChange
2026-06-09 NCT07326709
A Study to Investigate the Efficacy, Safety and Tolerability of Votoplam in Participants…
Trial sites expanded: 13 -> 20 locations
2026-06-06 NCT06868212
A Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in…
Trial sites expanded: 114 -> 128 locations
2026-06-02 NCT07225504
A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive…
Trial sites expanded: 200 -> 208 locations
2026-06-02 NCT06744920
A Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib Versus…
Trial sites expanded: 101 -> 129 locations
2026-05-30 NCT05156281
Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With…
date change Primary completion pushed: 2026-04-30 -> 2026-07-23
2026-05-30 NCT05147220
Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With…
date change Primary completion pushed: 2026-04-30 -> 2026-07-23
2026-05-28 NCT07225504
A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive…
Trial sites expanded: 187 -> 200 locations
2026-05-20 NCT07225504
A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive…
Trial sites expanded: 180 -> 187 locations
Active Studies by Phase
Phase 3
11
Phase 2
3
Active Trials
NCT IDTitleConditionStatus
Phase 3
NCT06744920 A Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib Versus… Generalized Myasthenia Gravis Recruiting
NCT07225504 A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive… Secondary Progressive Multiple Sclerosis (SPMS) Recruiting
NCT07456891 Remibrutinib Open Label Roll-over Post-trial Access Protocol Indication of the Parent Protocol Recruiting
NCT05677451 24 Weeks Double-blind Randomized Placebo-controlled Trial to Evaluate Efficacy, PK… Chronic Spontaneous Urticaria Recruiting
NCT06868212 A Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in… Chronic Spontaneous Urticaria (CSU) Recruiting
NCT07326709 A Study to Investigate the Efficacy, Safety and Tolerability of Votoplam in Participants… Huntington Disease Recruiting
NCT05513001 An Extension Study of Long-term Efficacy, Safety and Tolerability of Remibrutinib in… Chronic Spontaneous Urticaria Active, Not Recruiting
NCT05147220 Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With… Relapsing Multiple Sclerosis Active, Not Recruiting
NCT05156281 Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With… Relapsing Multiple Sclerosis Active, Not Recruiting
NCT06042478 Phase 3b Study to Assess the Efficacy, Safety, and Tolerability of Remibrutinib in… Chronic Spontaneous Urticaria Active, Not Recruiting
NCT05976243 A Study to Investigate Efficacy, Safety, and Tolerability of Remibrutinib Compared With… Chronic Inducible Urticaria Active, Not Recruiting
Phase 2
NCT06865651 Study of Remibrutinib (LOU064) Efficacy and Safety and Exploration of Its Mechanism of… Chronic Urticaria (CU): Chronic Inducible Urticaria (CINDU) and Chronic Spontaneous Urticaria (CSU) Recruiting
NCT03827798 Study of Efficacy and Safety of Investigational Treatments in Patients With Moderate to… Hidradenitis Suppurativa Active, Not Recruiting
NCT07222956 A Study of Remibrutinib Using MR Imaging in Relapsing or Progressive MS Multiple Sclerosis (MS) - Relapsing-remitting Not Yet Recruiting
Sponsors Running Remibrutinib Trials
Disease Areas
Get alerts when Remibrutinib trials change
Status changes, date slips, and new filings — detected daily, delivered to your inbox.
Start monitoring free